The prevalence of malnutrition in patients with lung cancer is particularly high, but early and intensive individualized dietary counseling can improve quality of life for these patients and decrease their chances of experiencing significant weight loss. Read More ›

If you cannot get your patients with lung cancer to stop smoking, at least encourage them to exercise. Read More ›

At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology at the Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery. Read More ›

Each year the Bonnie J. Addario Lung Cancer Foundation (ALCF) recognizes luminaries in the quest to cure lung cancer with the Addario Lectureship Award. Read More ›

Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation, and become resistant when treated with a tyrosine kinase inhibitor. Read More ›

What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population. Read More ›

This patient vignette portrays the self-blame, suffering, and personal pain that a diagnosis of lung cancer may precipitate in patients who smoked cigarettes for a significant part of their life. Lung cancers are the leading cause of cancer deaths in the United States Read More ›

There’s a lot we don’t know about lung cancer screening,” according to Denise Aberle, MD... However, certain measures can be taken to lower false-positive and overdiagnosis rates, lessen costs, ameliorate patient suffering, and correctly identify screening cohorts, she asserted. Read More ›

A 66-year-old female with newly diagnosed non-small cell lung cancer (NSCLC) presents to clinic. She is diagnosed with a stage IV adenocarcinoma. She was previously treated at an outside institution with pemetrexed in a clinical trial. Read More ›

In a phase 3 head-to-head comparison trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib proved more effective than standard chemo­therapy with pemetrexed or docetaxel as a second-line treatment for non–small cell lung cancer (NSCLC) patients with the ALK genetic abnormality. Read More ›